Following its announcement of five business wins at the start of the year, PRISYM ID has said that it has successfully implemented a further six new regulated labelling software systems as demand from across the medical device and life science sectors increases.
The labelling software firm says that this demonstrates the medical device and life science industries are recovering from the impact of the pandemic and are refocussing on implementing labelling management solutions to help prepare for the future.
The company adds that it sees the experience of the pandemic having an impact on the market as customers look for solutions that will increase their flexibility and allow them to respond more effectively to any change or uncertainty in their business over the months ahead.
In particular, many organisations are prioritising speed of implementation as they seek to implement solutions that can help them as they prepare for life post pandemic – as a result, PRISYM ID says that its customers are putting a far greater focus on so-called “time to value” for their technology investments than ever before.
Richard Adams, chief executive of PRISYM ID, said: “We are incredibly pleased to have delivered PRISYM 360 solutions across both our medical device and clinical trial supply sectors. The first few months of 2021 have been extremely busy for us as it is clear that the legacy of COVID-19 has focused people’s minds.
“For our customers, fast and agile implementation combined with specialist industry knowledge are extremely important, and the projects we have successfully executed in recent months show we can deliver the best of all worlds: high quality solutions, delivered at speed, by genuine experts in the field.”
